1
John McWhirter, Lynn MacDonald, Sean Stevens, Andrew J Murphy: Mice expressing a limited immunoglobulin light chain repertoire. Regeneron Pharmaceuticals, Choate Hall & Stewart, Brenda Herschbach Jarrell, Stephanie L Schonewald, October 24, 2017: US09796788 (1 worldwide citation)

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light ...


2
John McWhirter, Lynn MacDonald, Sean Stevens, Andrew J Murphy, Margaret Karow: Humanized universal light chain mice. Regeneron Pharmaceuticals, Choate Hall & Stewart, Brenda Herschbach Jarrell, Stephanie L Schonewald, November 20, 2018: US10130081

Mice, tissues, cells, and genetic material are provided that comprise a humanized heavy chain immunoglobulin locus, a humanized light chain locus that expresses a universal light chain, and a gene encoding an ADAM6 or ortholog or homolog or functional fragment thereof. Mice are provided that express ...


3
John McWhirter, Lynn MacDonald, Sean Stevens, Andrew J Murphy: Methods for making fully human bispecific antibodies using a common light chain. Regeneron Pharmaceuticals, Choate Hall & Stewart, Brenda Herschbach Jarrell, Stephanie L Schonewald, May 15, 2018: US09969814

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in ...


4
John McWhirter, Lynn Macdonald, Sean Stevens, David R Buckler, Andrew J Murphy: Common light chain mouse. Regeneron Pharmaceuticals, Choate Hall & Stewart, Brenda Herschbach Jarrell, Stephanie L Schonewald, December 4, 2018: US10143186

A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably l ...


5
John McWhirter, Lynn Macdonald, Sean Stevens, Andrew J Murphy: Mice expressing a limited immunoglobulin light chain repertoire. Regeneron Pharmaceuticals, Choate Hall & Stewart, Brenda Herschbach Jarrell, Stephanie L Schonewald, January 1, 2019: US10167344

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light ...


6
Lynn Macdonald, Cagan Gurer, Karolina A Hosiawa, Sean Stevens, Andrew J Murphy: Humanized light chain mice. REGENERON PHARMACEUTICALS, Choate Hall & Stewart, Brenda Herschbach Jarrell, Stephanie L Schonewald, July 18, 2017: US09706759

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variabl ...


7
Lynn Macdonald, Cagan Gurer, Karolina A Meagher, Sean Stevens, Andrew J Murphy: Humanized light chain mice. REGENERON PHARMACEUTICALS, Choate Hall & Stewart, Brenda Herschbach Jarrell, Stephanie L Schonewald, April 18, 2017: US09622459

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variabl ...


8
Todd Gierahn, Richard Malley: Vaccines and compositions against. Genocea Biosciences, Children s Medical Center Corporation, Choate Hall & Stewart, Rolando Medina, Stephanie L Schonewald, January 29, 2019: US10188717

Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromized patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically o ...


9
John Hamer, Wynne Weston Davies: Method of treating myasthenia gravis. Volution Immuno Pharmaceuticals, Choate Hall & Stewart, Fangli Chen, Stephanie L Schonewald, November 24, 2015: US09192648

The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of myasthenia gravis.


10
Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson: Engineered botulinum neurotoxin. PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Brenda Herschbach Jarrell, Stephanie L Schonewald, Choate Hall & Stewart, March 21, 2017: US09598685

Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E11 ...